Clinical

September 4, 2012

BioLineRx In-Licenses Biokine Novel, Phase II Ready Drug BKT140 for the Treatment of Leukemia, Other Hematological Cancers, and stem cell mobilization.

Pre- Clinical

BKT300- Novel anti-cancer agents.

Biokine is seeking continued funding for this project through collaboration and private and public investments.

BKT170- CXCR4 antagonist for the treatment of skin conditions.

Biokine will seek a co-development partner on this project.

BKT130- Promiscuous chemokine antagonist for age related macular degeneration (AMD).

Biokine will seek a co-development partner on this project.

wood_bkgd